NCT00605319View on ClinicalTrials.gov

An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia

PHASE4CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Bladder Outlet Obstruction
Interventions
DRUG

Toviaz (Fesoterodine)

4mg to 8mg by mouth once daily

Trial Locations (1)

10065

New York Hospital, Cornell University, New York

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER